What is Pluri Inc.'s market cap?

Pluri Inc. (PLUR) has a market capitalization of $17.7M and trades on NASDAQ.

Who are Pluri Inc.'s competitors?

Pluri Inc.'s key competitors include Charles River Laboratories International, Inc., Adicet Bio, Celularity Inc. Class A Common Stock, and others. These companies compete in similar markets and product categories.

Who does Pluri Inc. partner with?

Pluri Inc.'s notable partners include ICL Group Ltd., Takeda Pharmaceuticals International AG, Bühler Group, and others.

What subsidiaries does Pluri Inc. have?

Pluri Inc.'s subsidiaries include Pluri Biotech Ltd., Ever After Foods, Coffeesai Ltd., and others.

Where is Pluri Inc. headquartered?

Pluri Inc. is headquartered in Israel and employs approximately 134 people. It has been publicly traded since 1991.

Pluri Inc.

PLUR

Pluri Inc. is a biotechnology company that utilizes a proprietary 3D cell expansion platform to develop scalable, cell-based solutions across healthcare, food tech, and agriculture.

Market cap

$17.69M-57.0%

Table of contents

Earnings

Q1 2026 report

May 14, 2026

Revenue$167.0KMiss by $488.0K EPS-$0.55Beat by $0.11

Read the full report

Next report

Sep 23, 2026 (in 2 months)

Revenue estimate$655.0K

EPS estimate-$0.66

Competitors

By market cap

Charles River Laboratories$10.8B+22.9%

Sana Biotechnology$912.8M-17.1%

PRO

ProKidney Corp.$316.0M-23.1%

Adicet Bio, Inc.$75.3M+21.1%

Celularity$21.7M-72.4%

Longeveron$19.3M-21.6%

Pluri Inc.$17.7M-58.2%

Creative Medical Technology Holdings, Inc.$5.1M-24.7%

Profile

Pluri Inc. is a biotechnology company that utilizes a proprietary 3D cell expansion platform to develop scalable, cell-based solutions across healthcare, food tech, and agriculture. The company leverages its industrial-scale GMP manufacturing facility to produce placenta-based cell therapies and high-volume plant cell cultures. Its core value proposition lies in providing cost-effective, mass-scale cell production through a collaborative network of subsidiaries and joint ventures.

Competitive position

A technology leader in 3D cell expansion with a unique ability to scale placenta-derived and plant-based cells for diverse industrial applications.

GeographiesIsrael, United States, European Union, Japan, South Korea

Customer segmentsPharmaceutical companies, Biotech startups, Food manufacturers, Government defense agencies

Business modelB2B, Licensing, Contract Manufacturing (CDMO), Joint Venture

SuppliersHuman placenta donors, Synthetic scaffolds, Bioreactor components, Laboratory equipment suppliers

CustomersClinical trial sponsors, Hospitals, Food ingredient distributors, Strategic agricultural partners

CountryIsrael

Listed1991

Employees134.0

CEOYaacov Yanay

SectorHealthcare

IndustryBiotechnology

Websitepluri-biotech.com

FilingsSEC EDGAR

Questions, answered.

What is Pluri Inc.'s market cap?: Pluri Inc. (PLUR) has a market capitalization of $17.7M and trades on NASDAQ.
Who are Pluri Inc.'s competitors?: Pluri Inc.'s key competitors include Charles River Laboratories International, Inc., Adicet Bio, Celularity Inc. Class A Common Stock, and others. These companies compete in similar markets and product categories.
Who does Pluri Inc. partner with?: Pluri Inc.'s notable partners include ICL Group Ltd., Takeda Pharmaceuticals International AG, Bühler Group, and others.
What subsidiaries does Pluri Inc. have?: Pluri Inc.'s subsidiaries include Pluri Biotech Ltd., Ever After Foods, Coffeesai Ltd., and others.
Where is Pluri Inc. headquartered?: Pluri Inc. is headquartered in Israel and employs approximately 134 people. It has been publicly traded since 1991.